Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs.54(Suppl. 4),1–7 (1997).
  Medline CASGoogle Scholar
• 2  Maluf FC, Spriggs D. Anthracyclines in the treatment of gynecologic malignancies. Gynecol. Oncol.85(1),18–31 (2002).
  Medline CASGoogle Scholar
• 3  Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the anti-tumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol.57(7),727–741 (1999).
  Medline CASGoogle Scholar
• 4  Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J.4(13),3076–3086 (1990).
  Medline CASGoogle Scholar
• 5  Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov.7(9),771–782 (2008).▪▪ Good review that highlights the features of nanoparticle therapeutics that distinguish them from previous anticancer therapies and describes how these features provide the potential for therapeutic effects.
  Medline CASGoogle Scholar
• 6  Peer D, Karp JM, Hong S et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol.2(12),751–760 (2007).▪▪ Good review that examines some of the approved formulations and discusses the challenges in translating basic research to the clinic.
  Medline CASGoogle Scholar
• 7  Maeda H, Wu J, Sawa T et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Release65(1–2),271–284 (2000).▪ Key publication on the mechanism the significance of enhanced permeation and retention effect.
  Medline CASGoogle Scholar
• 8  Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev.60(15),1615–1626 (2008).
  Medline CASGoogle Scholar
• 9  Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer.99(3),392–397 (2008).
  Medline CASGoogle Scholar
• 10  Batist G, Barton J, Chaikin P et al. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin. Pharmacother.3(12),1739–1751 (2002).
  Medline CASGoogle Scholar
• 11  Leonard RC, Williams S, Tulpule A et al. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast.18(4),218–224 (2009).
  Medline CASGoogle Scholar
• 12  James ND, Coker RJ, Tomlinson D et al. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi’s sarcoma in AIDS. Clin. Oncol. (R. Coll. Radiol.)6(5),294–296 (1994).
  Medline CASGoogle Scholar
• 13  Tejada-Berges T, Granai CO, Gordinier M et al. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev. Anticancer Ther.2(2),143–150 (2002).
  Medline CASGoogle Scholar
• 14  Sutton D, Nasongkla N, Blanco E et al. Functionalized micellar systems for cancer targeted drug delivery. Pharm. Res.24(6),1029–1046 (2007).▪ Provides a review on functionalized micelles for tumor-targeted delivery.
  Medline CASGoogle Scholar
• 15  Sparano JA, Winer EP. Liposomal anthracyclines for breast cancer. Semin. Oncol.28(4 Suppl. 12),32–40 (2001).
  Medline CASGoogle Scholar
• 16  Batist G, Ramakrishnan G, Rao CS et al. Reduced cardiotoxicity and preserved anti-tumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol.19(5),1444–1454 (2001).
  Medline CASGoogle Scholar
• 17  Harris L, Batist G, Belt R et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer.94(1),25–36 (2002).
  Medline CASGoogle Scholar
• 18  Chan S, Davidson N, Juozaityte E et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann. Oncol.15(10),1527–1534 (2004).
  Medline CASGoogle Scholar
• 19  Elbayoumi TA, Torchilin VP. Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice. Int. J. Pharm.357(1–2),272–279 (2008).
  Medline CASGoogle Scholar
• 20  Cheng WW, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab’ fragments and single chain Fv. J. Control Release.126(1),50–58 (2008).
  Medline CASGoogle Scholar
• 21  Yamada A, Taniguchi Y, Kawano K et al. Design of folate-linked liposomal doxorubicin to its anti-tumor effect in mice. Clin. Cancer Res.14(24),8161–8168 (2008).
  Medline CASGoogle Scholar
• 22  Schiffelers RM, Koning GA, ten Hagen TL et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control Release.91(1–2),115–122 (2003).
  Medline CASGoogle Scholar
• 23  Allen TM, Mumbengegwi DR, Charrois GJ. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin. Cancer Res.11(9),3567–3573 (2005).
  Medline CASGoogle Scholar
• 24  Pastorino F, Brignole C, Marimpietri D et al. Doxorubicin-loaded Fab’ fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res.63(1),86–92 (2003).
  Medline CASGoogle Scholar
• 25  Murphy EA, Majeti BK, Barnes LA et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl Acad. Sci. USA105(27),9343–9348 (2008).
  Medline CASGoogle Scholar
• 26  Lee TY, Lin CT, Kuo SY et al. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res.67(22),10958–10965 (2007).
  Medline CASGoogle Scholar
• 27  Moreira JN, Gaspar R. Antagonist G-mediated targeting and cytotoxicity of liposomal doxorubicin in NCI-H82 variant small cell lung cancer. Braz. J. Med. Biol. Res.37(8),1185–1192 (2004).
  Medline CASGoogle Scholar
• 28  Kobayashi T, Ishida T, Okada Y et al. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int. J. Pharm.329(1–2),94–102 (2007).
  Medline CASGoogle Scholar
• 29  Saul JM, Annapragada A, Natarajan JV et al. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J. Control Release.92(1–2),49–67 (2003).
  Medline CASGoogle Scholar
• 30  Gabizon A, Tzemach D, Gorin J et al. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother. Pharmacol.66(1),43–52 (2010).
  Medline CASGoogle Scholar
• 31  Peer D, Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the anti-tumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia.6(4),343–353 (2004).
  Medline CASGoogle Scholar
• 32  Eliaz RE, Szoka FC Jr. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res.61(6),2592–2601 (2001).
  Medline CASGoogle Scholar
• 33  Song CK, Jung SH, Kim DD et al. Disaccharide-modified liposomes and their in vitro intracellular uptake. Int. J. Pharm.380(1–2),161–169 (2009).
  Medline CASGoogle Scholar
• 34  Elbayoumi TA, Torchilin VP. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur. J. Pharm. Sci.32(3),159–168 (2007).
  Medline CASGoogle Scholar
• 35  Lukyanov AN, Elbayoumi TA, Chakilam AR et al. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J. Control Release.100(1),135–144 (2004).
  Medline CASGoogle Scholar
• 36  Elbayoumi TA, Pabba S, Roby A et al. Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J. Liposome Res.17(1),1–14 (2007).
  Medline CASGoogle Scholar
• 37  Elbayoumi TA, Torchilin VP. Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. Mol. Pharm.6(1),246–254 (2009).
  Medline CASGoogle Scholar
• 38  Elbayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced anti-tumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin. Cancer Res.15(6),1973–1980 (2009).
  Medline CASGoogle Scholar
• 39  Pastorino F, Brignole C, Marimpietri D et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res.63(21),7400–7409 (2003).▪ Interesting paper on tumor vessel-targeted liposomal doxorubicin.
  Medline CASGoogle Scholar
• 40  Pastorino F, Brignole C, Di Paolo D et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res.66(20),10073–10082 (2006).▪ Interesting paper on tumor cell- and tumor vasculature-targeted liposomal doxorubicin.
  Medline CASGoogle Scholar
• 41  Loi M, Marchio S, Becherini P et al. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J. Control Release.145(1),66–73 (2010).
  Medline CASGoogle Scholar
• 42  Longmuir KJ, Haynes SM, Baratta JL et al. Liposomal delivery of doxorubicin to hepatocytes in vivo by targeting heparan sulfate. Int. J. Pharm.382(1–2),222–233 (2009).
  Medline CASGoogle Scholar
• 43  Cheong I, Huang X, Bettegowda C et al. A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science.314(5803),1308–1311 (2006).▪ Interesting paper on targeting drugs to tumors with bacteria.
  Medline CASGoogle Scholar
• 44  Cheong I, Huang X, Thornton K et al. Targeting cancer with bugs and liposomes: ready, aim, fire. Cancer Res.67(20),9605–9608 (2007).
  Medline CASGoogle Scholar
• 45  Wang Y, Wang R, Lu X et al. Pegylated phospholipids-based self-assembly with water-soluble drugs. Pharm. Res.27(2),361–370 (2010).
  Medline CASGoogle Scholar
• 46  Matsumura Y, Hamaguchi T, Ura T et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer.91(10),1775–1781 (2004).
  Medline CASGoogle Scholar
• 47  Kuroda J, Kuratsu J, Yasunaga M et al. Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma. Int. J. Cancer.124(11),2505–2511 (2009).
  Medline CASGoogle Scholar
• 48  Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv. Drug Deliv. Rev.60(8),899–914 (2008).▪ Good review on poly(amino acid) micelles in preclinical and clinical studies.
  Medline CASGoogle Scholar
• 49  Danson S, Ferry D, Alakhov V et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer.90(11),2085–2091 (2004).
  Medline CASGoogle Scholar
• 50  Kim DW, Kim SY, Kim HK et al. Multicenter Phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol.18(12),2009–2014 (2007).
  MedlineGoogle Scholar
• 51  Lee KS, Chung HC, Im SA et al. Multicenter Phase II trial of Genexol-PM, a cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat.108(2),241–250 (2008).
  Medline CASGoogle Scholar
• 52  Valle JW, Armstrong A, Newman C et al. A Phase II study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest New Drugs. DOI: 10.1007/s10637-010-9399-9391 (2010) (Epub ahead of print).
  MedlineGoogle Scholar
• 53  Tang N, Du G, Wang N et al. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J. Natl Cancer Inst.99(13),1004–1015 (2007).
  Medline CASGoogle Scholar
• 54  Tsukioka Y, Matsumura Y, Hamaguchi T et al. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil). Jpn J. Cancer Res.93(10),1145–1153 (2002).
  Medline CASGoogle Scholar
• 55  Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Control Release.96(2),273–283 (2004).
  Medline CASGoogle Scholar
• 56  Yoo HS, Park TG. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J. Control Release.100(2),247–256 (2004).
  Medline CASGoogle Scholar
• 57  Tsai HC, Chang WH, Lo CL et al. Graft and diblock copolymer multifunctional micelles for cancer chemotherapy and imaging. Biomaterials31(8),2293–2301 (2010).
  Medline CASGoogle Scholar
• 58  Kim D, Gao ZG, Lee ES et al.In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Mol. Pharm.6(5),1353–1362 (2009).
  Medline CASGoogle Scholar
• 59  Kim D, Lee ES, Oh KT et al. Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small4(11),2043–2050 (2008).
  Medline CASGoogle Scholar
• 60  Nasongkla N, Shuai X, Ai H et al. cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem. Int. Ed. Engl.43(46),6323–6327 (2004).
  Medline CASGoogle Scholar
• 61  Nasongkla N, Bey E, Ren J et al. Multi
functional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett.6(11),2427–2430 (2006).
  Medline CASGoogle Scholar
• 62  Xiong XB, Ma Z, Lai R et al. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials31(4),757–768 (2010).
  Medline CASGoogle Scholar
• 63  Kataoka K, Matsumoto T, Yokoyama M et al. Doxorubicin-loaded poly(ethylene glycol)-poly(β-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J. Control Release64(1–3),143–153 (2000).
  Medline CASGoogle Scholar
• 64  Bae Y, Nishiyama N, Fukushima S et al. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo anti-tumor efficacy. Bioconjug. Chem.16(1),122–130 (2005).
  Medline CASGoogle Scholar
• 65  Hruby M, Konak C, Ulbrich K. Polymeric micellar pH-sensitive drug-delivery system for doxorubicin. J. Control Release103(1),137–148 (2005).
  Medline CASGoogle Scholar
• 66  Bae Y, Fukushima S, Harada A et al. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew Chem. Int. Ed. Engl.42(38),4640–4643 (2003).
  Medline CASGoogle Scholar
• 67  Bae Y, Jang WD, Nishiyama N et al. Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol. Biosyst.1(3),242–250 (2005).
  Medline CASGoogle Scholar
• 68  Lee ES, Na K, Bae YH. Polymeric micelle for tumor pH and folate-mediated targeting. J. Control Release.91(1–2),103–113 (2003).
  Medline CASGoogle Scholar
• 69  Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control Release103(2),405–418 (2005).
  Medline CASGoogle Scholar
• 70  Lee ES, Gao Z, Kim D et al. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J. Control Release129(3),228–236 (2008).▪ Interesting paper on super pH-sensitive multifunctional polymeric micelles.
  Medline CASGoogle Scholar
• 71  Lee ES, Na K, Bae YH. Super pH-sensitive multifunctional polymeric micelle. Nano Lett.5(2),325–329 (2005).
  Medline CASGoogle Scholar
• 72  Sethuraman VA, Bae YH. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J. Control Release.118(2),216–224 (2007).
  Medline CASGoogle Scholar
• 73  Holmgren L, O’Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med.1(2),149–153 (1995).
  Medline CASGoogle Scholar
• 74  Satchi-Fainaro R, Puder M, Davies JW et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med.10(3),255–261 (2004).
  Medline CASGoogle Scholar
• 75  Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat. Rev. Cancer5(6),423–435 (2005).
  Medline CASGoogle Scholar
• 76  Sengupta S, Eavarone D, Capila I et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature436(7050),568–572 (2005).▪ Interesting paper on the combination of chemotherapy and antiangiogenic therapy using nanotechnology.
  Medline CASGoogle Scholar
• 77  Mooney D. Cancer: one step at a time. Nature436,468–469 (2005).
  Medline CASGoogle Scholar
• 78  MacKay JA, Chen M, McDaniel JR et al. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat. Mater.8(12),993–999 (2009).
  MedlineGoogle Scholar
• 79  Park J, Fong PM, Lu J et al. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine5(4),410–418 (2009).
  Medline CASGoogle Scholar
• 80  Li YL, Zhu L, Liu Z et al. Reversibly stabilized multifunctional dextran nanoparticles efficiently deliver doxorubicin into the nuclei of cancer cells. Angew Chem. Int. Ed. Engl.48(52),9914–9918 (2009).
  Medline CASGoogle Scholar
• 81  Maeng JH, Lee DH, Jung KH et al. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials31(18),4995–5006 (2010).
  Medline CASGoogle Scholar
• 82  Kim B, Han G, Toley BJ et al. Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat. Nanotechnol.5,465–472 (2010).
  Medline CASGoogle Scholar
• 83  Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer.6(9),688–701 (2006).▪ Good review on polymer–anticancer drug conjugates.
  Medline CASGoogle Scholar
• 84  Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer5(3),161–171 (2005).
  Medline CASGoogle Scholar
• 85  Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today10(1),35–43 (2005).
  Medline CASGoogle Scholar
• 86  Lee CC, Gillies ER, Fox ME et al. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Natl Acad. Sci. USA103(45),16649–16654 (2006).▪ Interesting paper on doxorubicin-functionalized dendrimer.
  Medline CASGoogle Scholar
• 87  Kono K, Kojima C, Hayashi N et al. Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin. Biomaterials29(11),1664–1675 (2008).
  Medline CASGoogle Scholar
• 88  Kaneshiro TL, Lu ZR. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials30(29),5660–5666 (2009).
  Medline CASGoogle Scholar
• 89  Rapoport N, Pitt WG, Sun H et al. Drug delivery in polymeric micelles: from in vitro to in vivo. J. Control Release91(1–2),85–95 (2003).
  Medline CASGoogle Scholar
• 90  Husseini GA, Runyan CM, Pitt WG. Investigating the mechanism of acoustically activated uptake of drugs from Pluronic micelles. BMC Cancer2,20 (2002).
  MedlineGoogle Scholar
• 91  Marin A, Sun H, Husseini GA et al. Drug delivery in pluronic micelles: effect of high-frequency ultrasound on drug release from micelles and intracellular uptake. J. Control Release84(1–2),39–47 (2002).
  Medline CASGoogle Scholar
• 92  Rapoport NY, Herron JN, Pitt WG et al. Micellar delivery of doxorubicin and its paramagnetic analog, ruboxyl, to HL-60 cells: effect of micelle structure and ultrasound on the intracellular drug uptake. J. Control Release58(2),153–162 (1999).
  Medline CASGoogle Scholar
• 93  Ferrara KW. Driving delivery vehicles with ultrasound. Adv. Drug Deliv. Rev.60(10),1097–1102 (2008).
  Medline CASGoogle Scholar
• 94  Frenkel V. Ultrasound mediated delivery of drugs and genes to solid tumors. Adv. Drug Deliv. Rev.60(10),1193–1208 (2008).
  Medline CASGoogle Scholar
• 95  Vandenbroucke RE, Lentacker I, Demeester J et al. Ultrasound assisted siRNA delivery using PEG-siPlex loaded microbubbles. J. Control Release126(3),265–273 (2008).
  Medline CASGoogle Scholar
• 96  Lentacker I, Vandenbroucke RE, Lucas B et al. New strategies for nucleic acid delivery to conquer cellular and nuclear membranes. J. Control Release.132(3),279–288 (2008).
  Medline CASGoogle Scholar
• 97  Lentacker I, Geers B, Demeester J et al. Design and evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin delivery: cytotoxicity and mechanisms involved. Mol. Ther.18(1),101–108 (2010).
  Medline CASGoogle Scholar
• 98  Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer4(6),423–436 (2004).▪ Good review on metronomic chemotherapy.
  Medline CASGoogle Scholar
• 99  Browder T, Butterfield CE, Kraling BM et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res.60(7),1878–1886 (2000).
  Medline CASGoogle Scholar
• 100  Italiano A, Toulmonde M, Lortal B et al. “Metronomic” chemotherapy in advanced soft tissue sarcomas. Cancer Chemother. Pharmacol.66(1),197–202 (2010).
  Medline CASGoogle Scholar
• 101  Munzone E, Di Pietro A, Goldhirsch A et al. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. Breast19(1),33–37 (2010).
  Medline CASGoogle Scholar
• 102  Allen TM, Cullis PR. Drug-delivery systems: entering the mainstream. Science303(5665),1818–1822 (2004).
  Medline CASGoogle Scholar